Abstract Number: 1957 • ACR Convergence 2024
Assessing Left Ventricular Hemodynamic Forces in Systemic Sclerosis Patients: Pilot Study
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease marked by inflammation, microvascular changes and fibrosis. Cardiac comorbidities are the leading cause of mortality. Early…Abstract Number: 0306 • ACR Convergence 2024
Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…Abstract Number: 1958 • ACR Convergence 2024
Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients
Background/Purpose: Cardiac sarcoidosis (CS) is an underdiagnosed condition characterized by the formation of non-caseating granuloma in the myocardium, potentially leading to arrhythmia, acute heart failure,…Abstract Number: 0347 • ACR Convergence 2024
Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are chronic inflammatory muscle diseases that may cause premature death due to progressive muscle weakness, lung disease, and disease and…Abstract Number: 2009 • ACR Convergence 2024
Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…Abstract Number: 0472 • ACR Convergence 2024
Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Background/Purpose: Heart failure (HF) is an important, underdiagnosed comorbidity, with increased morbidity and mortality rates in rheumatoid arthritis (RA) patients. The risk of developing HF…Abstract Number: 2026 • ACR Convergence 2024
Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: Increased disease activity by SLEDAI (Systemic Erythematosus Lupus Disease Activity Index) has been associated with higher cardiovascular risk (CVR) and atherosclerotic cardiovascular disease (ASCVD),…Abstract Number: 0556 • ACR Convergence 2024
Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis
Background/Purpose: Valve degeneration is prevalent in Spondylarthritis (SpA) patients according to descriptive studies, but it is also common in general population. Disease burden may be…Abstract Number: 2046 • ACR Convergence 2024
Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents
Background/Purpose: Recurrent pericarditis (RP) challenges pts and clinicians in terms of long-term management. Objective of this study was to evaluate the remission rate (drug-free for…Abstract Number: 1469 • ACR Convergence 2023
Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with SLE are at increased risk for cardiovascular disease (CVD). Population estimates of CVD in SLE remains limited for non-White racial/ethnic populations in…Abstract Number: 1486 • ACR Convergence 2023
Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)
Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…Abstract Number: 1620 • ACR Convergence 2023
Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab
Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…Abstract Number: 1728 • ACR Convergence 2023
A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis
Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…Abstract Number: 1799 • ACR Convergence 2023
Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain
Background/Purpose: Chronic pain affects 30% of all patients in developed countries, accounting for up to 35% of prescriptions in acute care settings. Non-opioid pain medications…Abstract Number: 2096 • ACR Convergence 2023
Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure
Background/Purpose: Elevated left ventricular (LV) mass (LVM) is an important precursor to clinical heart failure (HF) in the general population. In fact, rheumatoid arthritis (RA)…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 11
- Next Page »
